IL13RA2 and glioblastoma: Similarly, targeted knockdown of IL-13Rα2, which was validated by immunoblot analysis (Supplementary Fig. 3c), in primary EGFRvIII-positive Mayo clinic derived GBM patient tumor, resulted in reduced cell proliferation (Supplementary Fig. 3d) and thus further confirmed the notion that IL-13Rα2 augmented cellular proliferation in the presence of EGFRvIII.